Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients.

ABSTRACT:

Background

Metastatic sites influence response rates to immune checkpoint inhibitors (ICI) and survival, suggesting anatomical locations impact treatment outcomes. This study examines how baseline metastatic sites affect progression patterns and survival in melanoma patients receiving first-line ICI or BRAF/MEK inhibitors (BRAF/MEKi).

Methods

Metastatic site presence and lesion counts at baseline and progression were captured chronologically for 347 ICI-treated and 210 BRAF/MEKi-treated patients using a novel graph representation. This novel approach enabled systematic comparison of progression patterns post-therapy failure across patients by providing a standardized representation of patterns of progression in patients with distinct clinical histories. Associations of basel

SUBMITTER: Vergara IA 

PROVIDER: S-EPMC12637396 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature